
## Sebastian Brandner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6528146/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association between tissue hypoxia, perfusion restrictions, and microvascular architecture alterations with lesion-induced impairment of neurovascular coupling. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 526-539.	2.4	4
2	Glucocorticoid modulation of synaptic plasticity in the human temporal cortex of epilepsy patients: Does chronic stress contribute to memory impairment?. Epilepsia, 2022, 63, 209-221.	2.6	7
3	Parenchymatous hematoma in patients with atraumatic subarachnoid hemorrhage: Characteristics, treatment, and clinical outcomes. International Journal of Stroke, 2021, 16, 648-659.	2.9	2
4	Stent-Assisted Coiling Using Leo+ Baby Stent. Clinical Neuroradiology, 2021, 31, 409-416.	1.0	14
5	Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers. Neuropathology and Applied Neurobiology, 2021, 47, 471-487.	1.8	3
6	Pedicle Screw Instrumentation of the Cervicothoracic Junction in the Sitting Position using CT-guided Navigation: Application and Technical Aspects. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2021, 82, 176-181.	0.4	0
7	Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nature Communications, 2021, 12, 2148.	5.8	20
8	Operative variations in temporal lobe epilepsy surgery and seizure and memory outcome in 226 patients suffering from hippocampal sclerosis. Neurological Research, 2021, 43, 1-10.	0.6	5
9	Beyond Functional Impairment: Redefining Favorable Outcome in Patients with Subarachnoid Hemorrhage. Cerebrovascular Diseases, 2021, 50, 729-737.	0.8	7
10	Assessment of conformity of actual thoraco-lumbar pedicle screw dimensions to manufacturers' specifications. Science Progress, 2021, 104, 003685042110350.	1.0	0
11	In vitro performance of six combinations of adjustable differential pressure valves and fixed anti-siphon devices with and without vertical motion. Acta Neurochirurgica, 2020, 162, 2421-2430.	0.9	3
12	The Diagnostic and Therapeutic Role of Leptin and Its Receptor ObR in Glioblastoma Multiforme. Cancers, 2020, 12, 3691.	1.7	6
13	Long-Term Complications and Influence on Outcome in Patients Surviving Spontaneous Subarachnoid Hemorrhage. Cerebrovascular Diseases, 2020, 49, 307-315.	0.8	26
14	Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. Acta Neuropathologica, 2020, 140, 397-400.	3.9	85
15	In vitro performance of combinations of anti-siphon devices with differential pressure valves in relation to the spatial position. Acta Neurochirurgica, 2020, 162, 1033-1040.	0.9	2
16	World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Radiology, 2020, 296, 111-121.	3.6	62
17	Ex vivo assessment of the optical characteristics of human brain and tumour tissue. , 2020, , .		0
18	Survival and Seizure Control have improved for Adult Low-Grade Gliomas over the last eleven years. Neuro-Oncology, 2019, 21, iv4-iv4.	0.6	1

#	Article	IF	CITATIONS
19	Redistribution of <scp>EZH</scp> 2 promotes malignant phenotypes by rewiring developmental programmes. EMBO Reports, 2019, 20, e48155.	2.0	9
20	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathologica Communications, 2019, 7, 24.	2.4	101
21	Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. The Cochrane Library, 2019, , .	1.5	1
22	Transmissible human proteopathies: an expanding field. Diagnostic Histopathology, 2019, 25, 16-22.	0.2	7
23	Decision making in surveillance of high-grade gliomas using perfusion MRI as adjunct to conventional MRI and artificial intelligence Journal of Clinical Oncology, 2019, 37, 2054-2054.	0.8	1
24	Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. Scientific Reports, 2018, 8, 6108.	1.6	52
25	Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathologica, 2018, 135, 671-679.	3.9	80
26	Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein. Journal of the Neurological Sciences, 2018, 386, 4-11.	0.3	6
27	Visualization of CSF Flow with Time-resolved 3D MR Velocity Mapping in Aqueductal Stenosis Before and After Endoscopic Third Ventriculostomy. Clinical Neuroradiology, 2018, 28, 69-74.	1.0	9
28	Neurological update: gliomas and other primary brain tumours in adults. Journal of Neurology, 2018, 265, 717-727.	1.8	24
29	THUR 220â€To c or not to c. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A32.1-A32.	0.9	0
30	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 87.	3.0	13
31	Flat Panel Detector Computed Tomographyâ^Guided Placement of External Ventricular Drains Using the BrainLAB Headband and Precalibrated Disposable Stylet Instrument: A Cadaveric Feasibility Study. World Neurosurgery, 2018, 115, 324-328.	0.7	2
32	The role of diffusion tensor imaging for non-invasive IDH phenotyping in gliomas Journal of Clinical Oncology, 2018, 36, e24174-e24174.	0.8	2
33	The role of dynamic susceptibility contrast perfusion- weighted MRI in the estimation of IDH mutation in gliomas Journal of Clinical Oncology, 2018, 36, 12063-12063.	0.8	1
34	Variant Creutzfeldt–Jakob Disease in a Patient with Heterozygosity at <i>PRNP</i> Codon 129. New England Journal of Medicine, 2017, 376, 292-294.	13.9	127
35	Leprosy in a patient infected with HIV. Practical Neurology, 2017, 17, 135-139.	0.5	4
36	Prion disease: experimental models and reality. Acta Neuropathologica, 2017, 133, 197-222.	3.9	54

#	Article	IF	CITATIONS
37	Genetic and clinical characteristics of <i>NEFL</i> -related Charcot-Marie-Tooth disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 575-585.	0.9	34
38	Neurological outcome and frequency of overdrainage in normal pressure hydrocephalus directly correlates with implanted ventriculo-peritoneal shunt valve type. Neurological Research, 2017, 39, 601-605.	0.6	17
39	MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. Development (Cambridge), 2017, 144, 2141-2152.	1.2	58
40	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	3.9	12
41	H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell, 2017, 32, 684-700.e9.	7.7	192
42	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. Scientific Reports, 2017, 7, 14275.	1.6	27
43	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	5.8	115
44	Methods for Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2017, 1658, 311-346.	0.4	17
45	A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS. Cell Reports, 2017, 20, 411-426.	2.9	49
46	Neuronal and Peripheral Pentraxins Modify Glutamate Release and may Interact in Blood–Brain Barrier Failure. Cerebral Cortex, 2017, 27, 3437-3448.	1.6	34
47	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
48	Imaging features of spinal tanycytic ependymoma. Neuroradiology Journal, 2016, 29, 61-65.	0.6	10
49	Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage. Clinical Neurology and Neurosurgery, 2016, 145, 79-83.	0.6	51
50	Spatiotemporal Pattern of Human Cortical and Subcortical Activity during Early-Stage Odor Processing. Chemical Senses, 2016, 41, 783-794.	1.1	12
51	The pathological diagnosis of nerve biopsies: a practical approach. Diagnostic Histopathology, 2016, 22, 333-344.	0.2	4
52	Collinge et al. reply. Nature, 2016, 535, E2-E3.	13.7	3
53	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
54	Collinge et al. reply. Nature, 2016, 537, E9-E9.	13.7	1

#	Article	IF	CITATIONS
55	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	3.7	170
56	Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling. Scientific Reports, 2016, 6, 27378.	1.6	37
57	Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration. Human Molecular Genetics, 2016, 25, 291-307.	1.4	19
58	Inflammatory demyelination without astrocyte loss in MOG antibody–positive NMOSD. Neurology, 2016, 87, 229-231.	1.5	47
59	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin–proteasome system. Acta Neuropathologica, 2016, 131, 411-425.	3.9	51
60	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits <i>in vivo</i> . Open Biology, 2016, 6, 150202.	1.5	21
61	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	4.5	41
62	Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. JAMA Neurology, 2016, 73, 76.	4.5	60
63	Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 512-519.	0.9	58
64	Quantitative in vivo optical tomography of cancer progression & vasculature development in adult zebrafish. Oncotarget, 2016, 7, 43939-43948.	0.8	23
65	Identification of clinical target areas in the brainstem of prionâ€infected mice. Neuropathology and Applied Neurobiology, 2015, 41, 613-630.	1.8	11
66	A new functional classification system (FGA/B) with prognostic value for glioma patients. Scientific Reports, 2015, 5, 12373.	1.6	7
67	A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biology, 2015, 5, 150165.	1.5	39
68	Generation of brain tumours by Cre-mediated recombination of neural progenitors <i>in situ</i> with the tamoxifen metabolite endoxifen. DMM Disease Models and Mechanisms, 2015, 9, 211-20.	1.2	9
69	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	2.1	98
70	Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathogens, 2015, 11, e1004953.	2.1	27
71	A novel and rapid method for obtaining high titre intact prion strains from mammalian brain. Scientific Reports, 2015, 5, 10062.	1.6	51
72	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	13.7	144

#	Article	IF	CITATIONS
73	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	1.8	83
74	A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Human Molecular Genetics, 2015, 24, 1883-1897.	1.4	52
75	Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1059-1064.	3.3	63
76	World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment. British Journal of Neurosurgery, 2015, 29, 693-698.	0.4	41
77	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	3.9	237
78	Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy. European Journal of Radiology, 2015, 84, 1128-1136.	1.2	33
79	Clinical Course Score (CCS). Journal of Neurosurgical Anesthesiology, 2015, 27, 26-30.	0.6	3
80	latrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	3.7	92
81	PERIPHERAL NERVE BING-NEEL SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.59-e4.	0.9	3
82	THE NEUROPATHY SPECTRUM IN WALDENSTRöM'S MACROGLOBULINAEMIA. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.60-e4.	0.9	0
83	A novel HTRA1 exon 2 mutation causes loss of protease activity in a Pakistani CARASIL patient. Journal of Neurology, 2015, 262, 1369-1372.	1.8	17
84	MRI detection of prion protein plaques in variant Creutzfeldt-Jakob disease. Neurology, 2015, 84, 1498-1499.	1.5	3
85	Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	13.7	418
86	A Nonsense Mutation in Mouse Tardbp Affects TDP43 Alternative Splicing Activity and Causes Limb-Clasping and Body Tone Defects. PLoS ONE, 2014, 9, e85962.	1.1	18
87	Ventricular and Lumbar Cerebrospinal Fluid Concentrations of Alzheimer's Disease Biomarkers in Patients with Normal Pressure Hydrocephalus and Posttraumatic Hydrocephalus. Journal of Alzheimer's Disease, 2014, 41, 1057-1062.	1.2	33
88	Plasma Concentrations of the Amyloid-β Peptides in Young Volunteers: The Influence of the APOE Genotype. Journal of Alzheimer's Disease, 2014, 40, 1055-1060.	1.2	7
89	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. American Journal of Human Genetics, 2014, 95, 590-601.	2.6	75
90	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease AÎ <sup>2</sup> Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	1.7	68

#	Article	IF	CITATIONS
91	Nature Has No Principle—Inflammation Following Brain Injury Is Neither Good Nor Evil*. Critical Care Medicine, 2014, 42, 1958-1959.	0.4	0
92	Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain, 2014, 137, 44-56.	3.7	143
93	Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 486-492.	0.9	35
94	High-throughput, automated quantification of white matter neurons in mild malformation of cortical development in epilepsy. Acta Neuropathologica Communications, 2014, 2, 72.	2.4	24
95	White matter perivascular spaces. Neurology, 2014, 82, 57-62.	1.5	151
96	Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications, 2014, 5, 4347.	5.8	126
97	A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling. Journal of Cell Science, 2014, 127, 3397-3397.	1.2	5
98	Microglial Cx3cr1knockout reduces prion disease incubation time in mice. BMC Neuroscience, 2014, 15, 44.	0.8	28
99	Extended phenotypic spectrum of <i>KIF5A</i> mutations. Neurology, 2014, 83, 612-619.	1.5	92
100	Critical role for DOK1 in PDGF-BB stimulated glioma cell invasion via p130Cas and Rap1 signalling. Journal of Cell Science, 2014, 127, 2647-58.	1.2	15
101	Active and Silent Thyroid-Stimulating Hormoneâ´´Expressing Pituitary Adenomas: Presenting Symptoms, Treatment, Outcomes, and Recurrence. World Neurosurgery, 2014, 82, 1224-1231.	0.7	40
102	Variant Creutzfeldt-Jakob Disease With Extremely Low Lymphoreticular Deposition of Prion Protein. JAMA Neurology, 2014, 71, 340.	4.5	17
103	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson's Disease. Cell Metabolism, 2013, 17, 941-953.	7.2	277
104	Filamentous white matter prion protein deposition is a distinctive feature of multiple inherited prion diseases. Acta Neuropathologica Communications, 2013, 1, 8.	2.4	7
105	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	13.9	113
106	Rapidly progressive asymmetrical weakness in Charcot–Marie–Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy. Neuromuscular Disorders, 2013, 23, 399-403.	0.3	38
107	Epigenetic Regulation of Survivin by Bmi1 Is Cell Type Specific During Corticogenesis and in Gliomas. Stem Cells, 2013, 31, 190-202.	1.4	25
108	Asymmetric sensory ganglionopathy: A case series. Muscle and Nerve, 2013, 48, 145-150.	1.0	10

#	Article	IF	CITATIONS
109	Atypical Scrapie Prions from Sheep and Lack of Disease in Transgenic Mice Overexpressing Human Prion Protein. Emerging Infectious Diseases, 2013, 19, 1731-1739.	2.0	27
110	Inherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein. PLoS Pathogens, 2013, 9, e1003643.	2.1	46
111	Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ, The, 2013, 347, f5675-f5675.	3.0	246
112	Neuroprotein Dynamics in the Cerebrospinal Fluid: Intraindividual Concomitant Ventricular and Lumbar Measurements. European Neurology, 2013, 70, 189-194.	0.6	30
113	Brain-Derived Protein Concentrations in the Cerebrospinal Fluid: Contribution of Trauma Resulting from Ventricular Drain Insertion. Journal of Neurotrauma, 2013, 30, 1205-1210.	1.7	16
114	Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation <i>In Vitro</i> . Cancer Research, 2013, 73, 5834-5844.	0.4	28
115	Sod1 Deficiency Reduces Incubation Time in Mouse Models of Prion Disease. PLoS ONE, 2013, 8, e54454.	1.1	22
116	Mouse Models of Glioma Pathogenesis: History and State of the Art. , 2013, , 87-107.		0
117	Plasmacytoid Dendritic Cells Sequester High Prion Titres at Early Stages of Prion Infection. PLoS Pathogens, 2012, 8, e1002538.	2.1	41
118	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt–Jakob disease: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 340-341.	0.9	8
119	Overexpression of the <i>Hspa13</i> ( <i>Stch</i> ) gene reduces prion disease incubation time in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13722-13727.	3.3	21
120	PrP Antibodies Do Not Trigger Mouse Hippocampal Neuron Apoptosis. Science, 2012, 335, 52-52.	6.0	62
121	Mutation in FAM134B causing severe hereditary sensory neuropathy: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 119-120.	0.9	48
122	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain, 2012, 135, 819-832.	3.7	97
123	Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiology of Aging, 2012, 33, 828.e31-828.e44.	1.5	54
124	Diagnostic implications of histological analysis of neurosurgical aspirate in addition to routine resections. Neuropathology, 2012, 32, 44-50.	0.7	6
125	BAG3 mutations: another cause of giant axonal neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 210-216.	1.4	66
126	Processing of nerve biopsies: A practical guide for neuropathologists. , 2012, 31, 7-23.		56

#	Article	IF	CITATIONS
127	Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 230-232.	0.9	29
128	Structural correlates of active-staining following magnetic resonance microscopy in the mouse brain. NeuroImage, 2011, 56, 974-983.	2.1	28
129	Sex Effects in Mouse Prion Disease Incubation Time. PLoS ONE, 2011, 6, e28741.	1.1	13
130	Neuroprotection and neuroregeneration: What to expect from a stem cell-based therapy of acute brain injury*. Critical Care Medicine, 2011, 39, 2577-2578.	0.4	1
131	One Hundred and One Dysembryoplastic Neuroepithelial Tumors: An Adult Epilepsy Series With Immunohistochemical, Molecular Genetic, and Clinical Correlations and a Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2011, 70, 859-878.	0.9	125
132	A novel mutation in the nerveâ€specific 5′UTR of the <i>GJB1</i> gene causes Xâ€linked Charcotâ€Marieâ€To disease. Journal of the Peripheral Nervous System, 2011, 16, 65-70.	oth 1.4	24
133	c-Jun expression in human neuropathies: a pilot study. Journal of the Peripheral Nervous System, 2011, 16, 295-303.	1.4	51
134	Tau, prions and $A\hat{l}^2$ : the triad of neurodegeneration. Acta Neuropathologica, 2011, 121, 5-20.	3.9	84
135	Diversity of prion diseases: (no) strains attached?. Acta Neuropathologica, 2011, 121, 1-4.	3.9	6
136	Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study. Journal of Pathology, 2011, 223, 511-518.	2.1	22
137	Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2011, 43, 296-298.	1.0	10
138	Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain, 2011, 134, 1829-1838.	3.7	29
139	Behavioral and Other Phenotypes in a Cytoplasmic Dynein Light Intermediate Chain 1 Mutant Mouse. Journal of Neuroscience, 2011, 31, 5483-5494.	1.7	23
140	A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay. Journal of General Virology, 2011, 92, 718-726.	1.3	26
141	Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathologica, 2010, 120, 327-341.	3.9	64
142	In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results. European Urology, 2010, 57, 879-883.	0.9	11
143	Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. Journal of Magnetic Resonance Imaging, 2010, 32, 1054-1060.	1.9	28
144	Earlyâ€onset Lâ€dopaâ€responsive parkinsonism with pyramidal signs due to <i>ATP13A2, PLA2G6, FBXO7</i> and <i>spatacsin</i> mutations. Movement Disorders, 2010, 25, 1791-1800.	2.2	287

#	Article	IF	CITATIONS
145	Generation of a panel of antibodies against proteins encoded on human chromosome 21. Journal of Negative Results in BioMedicine, 2010, 9, 7.	1.4	0
146	Largeâ€scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. Journal of Pathology, 2010, 222, 380-387.	2.1	48
147	Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. Journal of the Peripheral Nervous System, 2010, 15, 164-175.	1.4	66
148	Bortezomibâ€induced inflammatory neuropathy. Journal of the Peripheral Nervous System, 2010, 15, 366-368.	1.4	32
149	Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO Journal, 2010, 29, 222-235.	3.5	192
150	Nanog, Gli, and p53: a new network of stemness in development and cancer. EMBO Journal, 2010, 29, 2475-2476.	3.5	28
151	Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nature Neuroscience, 2010, 13, 1365-1372.	7.1	158
152	Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. Journal of General Virology, 2010, 91, 2651-2657.	1.3	106
153	High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain, 2010, 133, 858-867.	3.7	138
154	Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Human Molecular Genetics, 2010, 19, 2228-2238.	1.4	163
155	Magnetization transfer ratio may be a surrogate of spongiform change in human prion diseases. Brain, 2010, 133, 3058-3068.	3.7	10
156	Heterozygosity at Polymorphic Codon 219 in Variant Creutzfeldt-Jakob Disease. Archives of Neurology, 2010, 67, 1021-3.	4.9	19
157	Spontaneous generation of mammalian prions. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14402-14406.	3.3	40
158	Abstract 5071: Defining the role of canonical MAPK signaling in glioma initiation and maintenance. , 2010, , .		0
159	An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. DMM Disease Models and Mechanisms, 2009, 2, 359-373.	1.2	91
160	Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. European Urology, 2009, 55, 1440-1449.	0.9	74
161	Cadherin-11 Up-Regulation in Overactive Bladder Suburothelial Myofibroblasts. Journal of Urology, 2009, 182, 190-195.	0.2	15
162	Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. Journal of General Virology, 2009, 90, 546-558.	1.3	58

#	Article	IF	CITATIONS
163	The origin of the prion agent of kuru: molecular and biological strain typing. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3747-3753.	1.8	39
164	Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10238-10243.	3.3	174
165	Kuru prions and sporadic Creutzfeldt–Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3885-3890.	3.3	62
166	Investigation of <i>Mcp1</i> as a Quantitative Trait Gene for Prion Disease Incubation Time in Mouse. Genetics, 2008, 180, 559-566.	1.2	23
167	A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3725-3739.	1.8	65
168	Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3755-3763.	1.8	47
169	First Report of Creutzfeldt-Jakob Disease Occurring in 2 Siblings Unexplained byPRNPMutation. Journal of Neuropathology and Experimental Neurology, 2008, 67, 838-841.	0.9	11
170	Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2008, 459, 197-227.	0.4	38
171	Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected Mice. Neuron, 2007, 53, 325-335.	3.8	246
172	Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella. Molecular and Cellular Neurosciences, 2007, 34, 400-408.	1.0	19
173	An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. BMC Developmental Biology, 2007, 7, 131.	2.1	17
174	ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO Journal, 2007, 26, 4891-4901.	3.5	126
175	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet, The, 2006, 368, 2061-2067.	6.3	374
176	PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Letters, 2006, 580, 3121-3128.	1.3	52
177	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain, 2006, 129, 1557-1569.	3.7	91
178	Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10759-10764.	3.3	68
179	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
180	Growth Retardation and Bilateral Cataracts Followed by Anaplastic Meningioma 23 Years after High-Dose Cranial and Whole-Body Irradiation for Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Journal of Neuro-Oncology, 2005, 74, 195-199.	1.4	10

#	Article	IF	CITATIONS
181	An enzyme–detergent method for effective prion decontamination of surgical steel. Journal of General Virology, 2005, 86, 869-878.	1.3	103
182	Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis*. Journal of Biological Chemistry, 2005, 280, 38851-38861.	1.6	123
183	An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes. Science, 2005, 309, 2033-2037.	6.0	390
184	Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. Journal of General Virology, 2004, 85, 2471-2478.	1.3	45
185	Human Prion Protein with Valine 129 Prevents Expression of Variant CJD Phenotype. Science, 2004, 306, 1793-1796.	6.0	246
186	Transgene-driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration and motor impairment. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3644-3649.	3.3	37
187	Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice. Molecular and Cellular Biology, 2004, 24, 9848-9862.	1.1	367
188	Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme. Journal of Neuro-Oncology, 2004, 67, 191-200.	1.4	88
189	Identification and characterization of a novel mouse prion gene allele. Mammalian Genome, 2004, 15, 383-389.	1.0	26
190	Primary cerebral leiomyosarcoma in a child. Pediatric Radiology, 2004, 34, 495-498.	1.1	22
191	Prion disease incubation time is not affected in mice heterozygous for a dynein mutation. Biochemical and Biophysical Research Communications, 2004, 326, 18-22.	1.0	14
192	Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet, The, 2004, 364, 1260-1262.	6.3	67
193	A 38-year-old man with a 9 month history of neurological and cognitive impairment. Lancet Neurology, The, 2003, 2, 189-194.	4.9	2
194	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	13.7	457
195	Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis. Science, 2003, 302, 871-874.	6.0	673
196	Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Molecular and Cellular Neurosciences, 2003, 24, 696-708.	1.0	108
197	CNS pathogenesis of prion diseases. British Medical Bulletin, 2003, 66, 131-139.	2.7	18
198	Rb and p107 are required for normal cerebellar development and granule cell survival but not for Purkinje cell persistence. Development (Cambridge), 2003, 130, 3359-3368.	1.2	52

#	Article	IF	CITATIONS
199	Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6985-6990.	3.3	190
200	Histological yield, complications, and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imaging. Journal of Neurosurgery, 2002, 97, 354-362.	0.9	71
201	Malignant MCLeod myopathy. Muscle and Nerve, 2002, 26, 424-427.	1.0	31
202	PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (Cambridge), 2002, 129, 3513-3522.	1.2	164
203	Prions—Role of the Peripheral Nervous System. Virus Research, 2001, 82, 53.	1.1	3
204	Spongiform encephalopathies: Insights from transgenic models. Advances in Virus Research, 2001, 56, 313-352.	0.9	15
205	Second Primary Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2001, 60, 208-215.	0.9	16
206	Neuroimaging of cerebellar liponeurocytoma. Journal of Neurosurgery, 2001, 95, 324-331.	0.9	39
207	Kell and XK immunohistochemistry in McLeod myopathy. Muscle and Nerve, 2001, 24, 1346-1351.	1.0	63
208	Normal neurogenesis and scrapie pathogenesis in neural grafts lacking the prion protein homologue Doppel. EMBO Reports, 2001, 2, 347-352.	2.0	57
209	Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene, 2001, 20, 5084-5086.	2.6	40
210	Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver International, 2000, 20, 346-348.	1.9	104
211	Neuroinvasion of Prions: Insights from Mouse Models. Experimental Physiology, 2000, 85, 705-712.	0.9	18
212	Hyperventilation due to mitochondrial myopathy. Journal of the Royal Society of Medicine, 2000, 93, 25-26.	1.1	1
213	Differentiation and Histological Analysis of Embryonic Stem Cellâ€Derived Neural Transplants in Mice. Brain Pathology, 2000, 10, 330-341.	2.1	37
214	Shrinking prions: new folds to old questions. Nature Medicine, 1999, 5, 486-487.	15.2	6
215	Synaptophysin in Choroid Plexus Epithelial Cells: No Useful Aid in Differential Diagnosis. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1111-1111.	0.9	8
216	Transgenic and Knockout Mice in Research on Prion Diseases. Brain Pathology, 1998, 8, 715-733.	2.1	38

#	ARTICLE	IF	CITATIONS
217	Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions. Cell, 1998, 93, 203-214.	13.5	506
218	Transgenic mice as research tools in neurocarcinogenesis. Journal of NeuroVirology, 1998, 4, 159-174.	1.0	8
219	Identification of the End Stage of Scrapie Using Infected Neural Grafts. Brain Pathology, 1998, 8, 19-27.	2.1	38
220	PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature, 1997, 389, 69-73.	13.7	251
221	Analysis of the Determinants of Neurotropism and Neurotoxicity of HFV in Transgenic Mice. Virology, 1996, 216, 338-346.	1.1	14
222	Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genetics, 1996, 12, 195-199.	9.4	156
223	Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature, 1996, 379, 339-343.	13.7	756
224	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 1995, 54, 91-95.	0.9	306
225	Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia, 1995, 15, 348-364.	2.5	23
226	The AMOC/β2 subunit of Na, K-ATPase is not necessary for long-term survival of telencephalic grafts. Glia, 1995, 15, 377-388.	2.5	18
227	Symptomatic cerebellar metastasis and late local recurrence of a cauda equina paraganglioma. Journal of Neurosurgery, 1995, 83, 166-169.	0.9	44
228	Transgenic and Knockâ€out Mice: Models of Neurological Disease. Brain Pathology, 1994, 4, 3-20.	2.1	59
229	Neuro-Oncology. , 0, , 771-822.		1